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increased lactate levels and a reduction of metabolites asso-
ciated with the tricarboxylic acid cycle. This was confirmed 
by increased expression of glycolytic enzymes includ-
ing pyruvate dehydrogenase kinase in the treated tumors. 
Interestingly, l-glutamine levels were also reduced. These 
results were further confirmed by the assessment of in vivo 
metabolic data obtained by magnetic resonance spectros-
copy and positron emission tomography. Moreover, beva-
cizumab led to a depletion in glutathione levels indicating 
that the treatment caused oxidative stress in the tumors. 
Confirming the metabolic flux results, immunohistochemi-
cal analysis showed an up-regulation of lactate dehydro-
genase in the bevacizumab-treated tumor core as well 
as in single tumor cells infiltrating the brain, which may 
explain the increased invasion observed after bevacizumab 
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treatment. These observations were further validated in a 
panel of eight human GBM patients in which paired biopsy 
samples were obtained before and after bevacizumab treat-
ment. Importantly, we show that the GBM adaptation to 
bevacizumab therapy is not mediated by clonal selec-
tion mechanisms, but represents an adaptive response to 
therapy.
Keywords Glioblastoma · Bevacizumab · Metabolism · 
Adaptation
Introduction
In recent years, various -omics and deep sequencing tech-
nologies have provided important new insight into molecular 
sub-classifications of GBMs that have led to better prognos-
tic information. However, less is known about the mecha-
nisms of adaptability of tumor cells to changes in the micro-
environment and how these changes affect the tumor cell 
populations. Such changes may either arise due to alterations 
in the microenvironment during tumor progression, or as a 
response to therapy. During the last few years, the vascular 
endothelial growth factor (VEGF) inhibitor bevacizumab 
has been extensively applied for the treatment of recurrent 
GBMs. Yet, recent results from two double-blind, placebo-
controlled phase III trials, AVAglio [6] and RTOG 0825 [15], 
show that bevacizumab treatment does not increase overall 
survival, but leads to a minor increase in progression-free 
survival. GBMs are characterized by their diffuse infiltrative 
growth as well as extensive angiogenesis where VEGF has 
been shown to play a major role [45]. Thus, from a theoreti-
cal viewpoint, blocking the formation of new blood vessels 
should be beneficial for GBM patients and, indeed, dra-
matic effects are seen, exemplified by a strong reduction in 
contrast enhancement (CE) as well as vessel diffusion and 
perfusion, assessed by magnetic resonance imaging (MRI) 
following treatment [2, 8, 9, 12, 54, 57]. However, the exact 
mechanism by which GBMs evade bevacizumab treatment 
still remains enigmatic. Nevertheless, during the last decade 
intensive research has led to new insight into putative escape 
mechanisms. This includes: (i) escape via different modes of 
vascularization mediated by sprouting angiogenesis, vasculo-
genesis, vessel co-option and vascular mimicry (reviewed in 
[32, 51]); (ii) recruitment of pro-angiogenic myelogenic cells 
from the circulation [44]; (iii) secretion of numerous alter-
native pro-angiogenic factors such as bFGF, PIGF, Ephrins, 
PDGF-C, SDF-1α (reviewed in [33] and others [21, 31, 35]. 
Also, increased glioma cell invasion has been seen follow-
ing suppressed VEGF signaling [8, 27, 47, 48]. For instance, 
a relative hostile hypoxic microenvironment induced by 
anti-angiogenic therapy may lead to an up-regulation of pro-
invasive programs characterized by c-MET/HGF-induced 
mesenchymal transformation [24, 43], β1-integrin up-reg-
ulation [23] and increased MMP expression [13]. To add 
to this complexity, we have previously shown in a human 
GBM-derived xenograft model (that recapitulates the geno-
type and phenotype of the corresponding patient tumors) that 
vascular remodeling induced by anti-VEGF treatment leads 
to a more hypoxic tumor microenvironment which appears 
to favor metabolic changes in the tumors toward glycolysis, 
and where the net result is increased tumor cell invasion into 
the normal brain [27]. To study how bevacizumab affects 
the GBM metabolism, we performed 13C6-glucose injec-
tions into tumor-bearing animals, followed by LC–MS based 
metabolomic analysis to determine in detail metabolic flux 
and steady-state metabolites in tumor extracts after treat-
ment. To assess tumor growth, we also used complementary 
in vivo imaging methods including MRI and PET. Moreover, 
to determine if the observed changes in metabolism were 
caused by an adaptive response or clonal selection events 
within the tumors, we performed a flow cytometric ploidy 
analysis and multiparameter phenotyping on treated and 
non-treated tumors.
Materials and methods
Tumor material
Organotypic biopsy spheroids from human GBMs were 
prepared as previously described [4, 27] Briefly, tumor 
samples were minced into ~0.2 mm fragments and placed 
into tissue culture flasks base coated with 0.75 % agar 
(Difco, Detroit, MI, USA). The spheroids were maintained 
on agar pre-coated flasks in spheroid medium (DMEM 
medium, 10 % FBS, 2 mM l-glutamine, 0.4 mM NEAA 
and 100 U/ml Pen-Strep) for 7–10 days, in a standard tis-
sue culture incubator with 5 % CO2 and 100 % relative 
humidity at 37 °C. The spheroids used in the present study 
were derived from two GBM patients (P3 and P13) and 
expanded through serial transplantations in Rowett nude 
rats (RNU). This generated a standardized pool of sphe-
roids (300–400 µm in diameter) giving rise, after orthotopic 
xenografting, to highly invasive and angiogenic tumors 
[58] that show a similar DNA copy number as seen in 
human GBMs (Supplementary Fig. 1). The collection of 
human biopsy tissue was approved by the regional ethical 
committee at Haukeland University Hospital, Bergen, Nor-
way (REK 013.09).
Intracranial implantation
The P3 and P13 spheroids were stereotactically implanted 
into the brains of nude rats (n = 28 for P3 and n = 11 for 
P13) as well as in eGFP NOD/SCID mice (n = 5 for P3) 
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as described previously [16, 40, 58] Briefly, GBM sphe-
roids (10 per rat, 6 per mouse) were implanted into the 
right cerebral cortex using a Hamilton syringe fitted with a 
needle (Hamilton, Bonaduz, Switzerland). The handling of 
the animals and the surgical procedures were performed in 
accordance with the Norwegian Animal Act and the Euro-
pean Directive on animal experimentation (2010/63/EU) 
and the local ethical committee approved the protocol.
Bevacizumab treatment and sacrifice
Tumor take in rats was verified by MRI 3 weeks post-
implantation and animals were stratified into control 
(n = 13 for P3 and n = 6 for P13) and treatment groups 
(n = 15 for P3 and n = 5 for P13). Animals from the treat-
ment group received one weekly i.v injection of bevaci-
zumab (10 mg/kg) into the tail vein for 3 weeks. The con-
trol animals received saline following the same schedule. 
When symptoms developed, the rats were examined by 
MRI and subsequently killed; the brains were dissected 
out and cut into two pieces along the coronal plane at the 
tumor core. One piece was collected and fixed for histolog-
ical and immunohistological analyses (overnight fixation in 
4 % PFA) and the other was snap frozen in liquid N2 for 
13C6-glucose metabolic flux analysis. For the flux analysis, 
tumor tissue was collected from the tumor core as well as 
from the contralateral brain. Eight non-tumor bearing ani-
mals were divided into a treatment and a control group as 
above (n = 4, both groups) and treated for 3 weeks accord-
ingly before killing and tissue processing (see Fig. 1 for 
details). The GFP-expressing NOD/Scid mice received 
weekly intraperitoneal injections of bevacizumab (20 mg/
kg in saline), starting 3 weeks after spheroid implantation. 
Control animals received injections of saline. The mice 
were killed on appearance of neurological symptoms.
Western blot analyses
Snap-frozen tumor tissue extracts (tumor cells confirmed 
by HE-staining) were put in Kinexus Lysis Buffer and 
homogenized using a pellet pestle motor. Protein concen-
trations were determined using the BCA Protein assay kit 
(Pierce, BioRad, Oslo, Norway). Proteins (20–25 μg) were 
separated by SDS/PAGE using NuPage precast gels (Invit-
rogen) and transferred to nitrocellulose membranes. Mem-
branes were blocked for 1 h at RT in blocking buffer (5 % 
milk powder or 5 % BSA in TBS with 0.1 % Tween-20) 
and incubated overnight at 4 °C, with anti-LDHA diluted 
1:500 (Cell Signaling Technology, #3582, Leiden, the 
Netherlands), anti-PFKP 1:700 (Cell Signaling, #8164), 
anti-TKT 1:700 (Cell Signaling, #8616), anti-HKII 1:500 
(Abcam, #ab37593, Cambridge, UK), anti-ALDOC 1:500 
Fig. 1  Schematic representa-
tion of the experimental design. 
Three weeks after implantation, 
tumor growth was assessed by 
MRI. The rats were then treated 
weekly with bevacizumab 
(10 mg/kg) for 3 weeks. During 
the first week of treatment, 
8F-FMISO and 18F-FDG PET 
were performed at day 0, 3 
and 7. At week 6, the animals 
underwent MRI. Before killing, 
the animals were infused i.v 
with 13C6-glucose, whereupon 
the brains were harvested at 
15 min at 120 min after infusion 
for further analysis. For the flux 
analysis, tumor tissue was col-
lected both from the tumor core 
as well as from the contralateral 
brain (lower panel)
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(Sigma-Aldrich, #HPA00328, Oslo, Norway), anti-PDK1 
1:1500 (Sigma-Aldrich, #HPA027376) and anti-β-actin 
1:1000 (Abcam #ab8227) in blocking buffer. The primary 
antibodies were detected using an HRP-conjugated goat 
anti-rabbit secondary antibody (Immunotech, #IM0831, 
Brea, CA, USA) diluted 1:20000. The blots were devel-
oped using Pierce Supersignal West Femto Chemilumines-
cent Substrate (Pierce Biotechnology, Rockford, IL, USA) 
and detected with a Fuji LAS 3000 Imager (Fuji Life Sci-
ence, Dusseldorf, Germany). The blots were quantified 
using Fuji Multi Gauge software (Fuji Life Science) and 
analyzed (n = 2) with unpaired independent-samples t test 
(Excel software). Statistical significance was set at two lev-
els, *p < 0.1 and **p < 0.05.
Immunohistochemistry
Paraffin-embedded formalin-fixed tissue sections were 
deparaffinized and heated at 99 °C for 20 min in 10 mM 
citrate buffer at pH 6.0 or incubated with proteinase K 
diluted in 0.05 M Tris–Cl, pH 7.5 at 37 °C for 10 min. The 
sections were incubated with the following primary anti-
bodies: anti-human nestin (MAB5326; Millipore; 1:1000 
Billerica, MA, USA), anti-von Willebrand factor (A0082; 
DAKO; 1:1000, Oslo, Norway), anti-LDHA (3582; Cell 
Signaling, 1:200) and pimonidazole (Hypoxyprobe 9.7.11, 
HPI Inc, 1:200, Burlington, MA, USA). Primary antibodies 
were incubated for 90 min at RT. Detection was performed 
using a biotinylated secondary antibody (Vector Laborato-
ries, Trondheim, Norway) amplified with Vectastain ABC 
Reagent (Vector). Sections were developed using 3′3-diam-
inobenzidine (DAB, DAKO), following the manufacturer’s 
instructions. The quantification of vessel area fractions was 
analyzed in five microscopic high power fields for each 
section. Quantification of invasion was performed by delin-
eating the tumor core and counting nestin-positive cells 
outside the tumor core. Analysis was performed on five 
microscopic high-power fields for each section. The immu-
nohistochemical stainings were analyzed and pictures were 
taken with a Nikon light microscope (Nikon Eclipse E600, 
Melville, NY, USA) using Nikon imaging software (Nikon 
NIS Elements v 4.11).
Determination of NADP+/NADPH ratio
For the relative quantification of the oxidized and reduced 
adenine dinucleotide phosphates (NADP+ and NADPH) in 
tissue extracts, we used a bioluminescent assay NADP+/
NADPH-Glo™ Assay (Promega, G9081). Luminescence 
signals were measured in a 96-well format in a LUMIstar 
plate reader. Total oxidized and reduced nicotinamide 
amounts expressed in relative luminescence units served 
to determine NADP+/NADPH ratios in tissue extracts. 
Calibration of the assay was done with an NADP+ stand-
ard curve. For comparative analysis we used a standard-
ized extraction procedure as described by the manufacturer 
(25 μl extraction buffer per milligram of tissue).
MRI
Anatomical MRI sequences were acquired on a 7T Phar-
mascan (Bruker Biospin, Ettlingen, Germany), equipped 
with a quadratic rat head transmit/receive coil. Animals 
were anesthetized with 1–2 % isoflurane mixed with 50 % 
air and 50 % O2 and placed in a prone position in a cradle 
with a heating pad set at 37 °C. Breathing was monitored 
throughout the scanning sessions. Anatomical sequences 
used included T2-weighted (fast spin echo, TE/TR: 
36 ms/3,500 ms, in-plane resolution: 0.137 × 0.137 mm 
per pixel, slice thickness: 1 mm) as well as T1-weighted 
(fast spin echo, TE/TR: 7.5 ms/1,300 ms, in-plane resolu-
tion: 0.137 × 0.137 mm per pixel, slice thickness: 1 mm) 
before and after injection of a contrast agent (1 ml of undi-
luted gadodiamide, Omniscan, GE Healthcare, Stockholm, 
Sweden at 0.5 mmol/ml injected s.c). Magnetic resonance 
spectroscopy (MRS) data were acquired by 1H PRESS 
(TE/TR: 5.9 ms/2,500 ms in a single 3 × 3 × 3 mm3 voxel 
centered in the tumor, 256 averages) and analyzed with 
LCModel as previously described [27].
Positron emission tomography (PET) imaging
18F was produced by a local cyclotron (GE PETrace 840, 
Uppsala, Sweden) and used to synthesize 18F-fluoro-
deoxyglucose (18F-FDG) and 18F-fluoromisonidazole 
(18F-FMISO) using kits from ABX GmBH, Radeberg, Ger-
many. PET/CT sequences were acquired on a dedicated 
CT 80 W small animal Nanoscan PC imager from Mediso 
Medical Imaging Systems, Budapest, Hungary. CT X-ray 
images were acquired for animal positioning, anatomical 
reference and attenuation correction during PET data recon-
struction, using the following parameters: helical trajectory, 
tube voltage: 50 kVp, exposure time: 300 ms, 480 projec-
tions, binning 1:4 and matrix size 250 × 250 × 250 μm. 
Accumulation of 18F-FDG was measured for 40 min fol-
lowing the injection of 13.8 ± 1.3 MBq of activity. Injec-
tions of 18F-FMISO were performed the following day. 
29.3 ± 3.8 MBq of activity was injected, after which the 
animal was left awake for 120 min before the start of a 
30 min acquisition scans. This delay of 120 min had, in 
preliminary dynamic studies, been found to provide good 
tracer accumulation and tumor-to-brain tissue contrast. 
Activity doses were diluted in a saline solution and a vol-
ume of 1 ml was injected into the tail vein. Animals were 
anesthetized using 2.5 % sevoflurane mixed in air for the 
duration of the scans and monitored for breathing and 
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body temperature. Mediso Nucline software was used for 
PET data reconstruction from listmode using the following 
parameters: reconstruction algorithm 3D OSEM (6 itera-
tions), energy window 400–600 keV, coincidence mode 
1–5, corrections for random events, detector normalization, 
decay and dead time and voxel size 0.6 mm. Mediso Inter 
View Fusion software (version 2.02.055.2010) was used for 
data visualization, co-registration of PET and CT data and 
quantification of standard uptake values as in [59].
Metabolic flux analysis
U-13C6-glucose administration and definition of sampling 
time
U-13C6-glucose (Cambridge Isotope Laboratories, Tewks-
bury, MA, USA) was injected at a dose of 0.5 ml/100 g 
body weight using a 200 mg/ml glucose solution in 1× 
PBS for a single bolus injection in the tail vein. Blood sam-
ples of three normal rats were collected after 15, 30, 60 and 
120 min and the serum concentrations of 13C6-glucose were 
determined by LC–MS analysis (Supplementary Fig. 2). 
Based on this information, we decided to collect tissue 
samples after 15 and 120 min. In non-implanted control 
rats, brain tissue from the 15 min time point was collected.
Tissue and blood collection
The xenografts were immediately dissected out and cut in 
a frontal and posterior part at the site of implantation. One 
part of the brain was cryopreserved (transferred in isopen-
tane in liquid N2 immersion) or formalin fixed for histol-
ogy. From the second part, tumor and contralateral brain 
tissue fragments were dissected (average weight 93 mg) 
and transferred into cryotubes and frozen in liquid N2. For 
the animals without tumor, implantation tissues from both 
hemispheres were collected in the same manner. Blood 
samples were also taken intracardially at killing from all 
animals and maintained on dry ice in vacutainers before 
transfer to −80 °C.
Metabolite extraction
The collected tissue fragments were subdivided on ice 
in smaller fragments (10–20 mg) and transferred in 2 ml 
Eppendorf tubes for metabolite or nucleic acid extrac-
tions. For metabolite extraction, a 5 mm metal bead (Qia-
gen, No69989) and extraction buffer (methanol/acetonitrile/
water-50/30/20) containing 100 ng/ml HEPES for internal 
standard purpose (Sigma, H4034) was added to the tissue at 
a volume/weight ratio of 25 μl/mg. The tissue was disrupted 
in a bead mill (Qiagen, Tissuelyzer, Hombrechtikan, Switzer-
land) with two cycles (2 min/20 MHz) before vortexing on 
an Eppendorf Thermomixer at 2 °C/20 min/1,400 rpm. The 
extract was clarified by centrifugation (15 min/12k rpm/4 °C 
in an Eppendorf centrifuge) and transferred into fresh tubes 
for storage at −80 °C for LC–MS.
LC–MS analysis
The column used was the ZIC-pHILIC (150 × 2.1 mm id 
5 μm; SeQuant) with the guard column (20 × 2.1 mm id 
5 μm; Hichrom). Mobile phase A: 20 mM ammonia car-
bonate plus 0.1 % ammonia hydroxide in water. Mobile 
phase B: acetonitrile. The flow rate was kept at 100 μl/min 
and gradient as follows: 0 min 80 % of A, 30 min 20 % of 
B, 31 min 80 % of B and 45 min 80 % of B. The Exactive 
Orbitrap mass spectrometer (Thermo Scientific, Waltham, 
MA, USA) was operated in a polarity switching mode. All 
solvents were of HPLC grade purity.
Gene expression analysis
Total RNA was extracted using the RNeasy Plus Mini Kit 
(QIAGEN®, Germantown, MD). 1 μg of total RNA was 
reverse transcribed using iScript cDNA synthesis Kit (Bio-
rad) according to the manufacturer’s instructions and real-
time quantitative PCR (Q-PCR) was carried out using 
TaqMan® Fast Advanced Master Mix and the Viia™ 7 Real 
Time System (Applied Biosystems). See [26] for the oligo-
nucleotides used. The amplification temperature was kept at 
60 °C. Cycle threshold (Ct) values were determined in the 
exponential phase of the amplification curve and the ΔΔCT 
method was used for fold change calculations (QBase soft-
ware). RPLI3A was used as a housekeeping gene. Four 
(P13) to five (P3) animals per group were used and all sam-
ples were run in triplicate. Data were analyzed with unpaired 
independent-samples t test (Excel software). Statistical sig-
nificance was set at two levels, *p < 0.1 and **p < 0.05.
Patient data
We investigated paraffin sections from eight GBM patients at 
two time points. The first set of samples was obtained after 
primary surgery and the second after bevacizumab treatment 
(5 autopsy and 3 reoperations). LDH expression was exam-
ined by means of immunohistochemistry (for detailed patient 
characteristics and time of biopsy collection after bevaci-
zumab treatment see (Supplementary Table I). The study was 
approved by the local ethical committee of the Goethe Uni-
versity Frankfurt, Germany (GS 4/09; SNO_10-13).
Immunohistochemistry of patient biopsies
Immunohistochemistry on the tumor specimens was per-
formed using an automated staining system Discovery XT 
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(Roche/Ventana, Tucson, USA) as previously described [3]. 
Rabbit anti-human LDHA antibody (Cell Signaling #3582) 
was used as primary antibody.
Statistical analysis
The proportion of LDH-positive vs -negative cells in the 
GBM samples described above was determined by counting 
all cells using the Stereo Investigator as well as the Frac-
tionator (MicroBrightField Inc, Williston, USA), allowing 
for an unbiased evaluation of tumor areas. Counts from 
matched pairs of primary and recurrent post-bevacizumab 
tumors were analyzed using a paired t test. The same test 
was used to compare data from the metabolic flux analyses. 
Statistical significance of changes in MRS-identified lactate 
concentration was assessed by analysis of variance routines 
in Matlab (Mathworks, Natick, MA, USA) using the tumor 
volume and treatment as independent factors.
Ploidy analysis combined with cell membrane phenotyping
Flow cytometry experiments were performed as described 
before [16, 17]. Briefly, xenografts derived in eGFP-
expressing mice were minced with scalpels and dissociated 
with MACS Neural Tissue Dissociation Kit (P) (Miltenyi, 
130-092-628, Lund, Sweden) following the manufacturer’s 
instructions. Single cell suspensions were incubated with 
Hoechst 33342 (5 µg/ml, Bisbenzimide, Ho342; Sigma) 
at 37 °C in pre-warmed DMEM, containing 2 % FBS, 
10 mM HEPES pH 7.4 and DNAse I (10 µg/ml; Sigma) 
at 1 × 106 cells/ml for 120 min. After washing, cells 
were resuspended in ice-cold HBSS 2 % FBS and 10 mM 
HEPES pH 7.4 buffer (100 µl/test). Prior to flow cytometry, 
cells were incubated with LIVE/DEAD® Fixable Dead Cell 
Stains (Life Technologies) and appropriate preconjugated 
antibodies for 30 min at 4 °C in the dark (antibodies are 
listed in Supplementary Table II). Data acquisition was 
performed on a FACS Aria™ SORP cytometer (BD Bio-
sciences, San Jose, CA, USA) and the Hoechst signal was 
excited with the UV laser. Data acquisition and analysis 
were done with DIVA software (BD Biosciences). Histo-
grams were prepared with the FlowJo software.
Results
Bevacizumab induces reduction of contrast enhancement 
and normalization of vascular morphology
We have previously established a human GBM xenograft sys-
tem that at the level of DNA copy number variation closely 
reflects the corresponding human tumors in situ [49, 58]. 
Of the two GBMs used here, one (P3) was of mesenchymal 
subtype and the other (P13) of neural subtype. P3 shows tri-
somy of Chr7, Chr19, 20q, homozygous deletion of 1q42-q43, 
Chr9, Chr10, 20p and loss of PIK3R1 and CDKN2A/B. P13 
harbors trisomy of Chr7, Chr19, Chr20, homozygous dele-
tion of 6q16.2–16.3, Chr10, 17q12 and loss of CDKN2A/B 
(Supplementary Fig. 1). The untreated P3 and P13 xenografts 
showed typical hallmarks of GBMs as indicated by pseudo-
palisading necrotic areas and microvascular proliferations. 
After bevacizumab treatment, MRI confirmed observations 
obtained from numerous clinical as well as experimental stud-
ies showing a reduction in contrast enhancement (Fig. 2a, 
upper panel). Interestingly, histological analysis of the bevaci-
zumab-treated tumors revealed a reduction of necrotic areas in 
the P3 tumors, whereas in the P13 tumors, extensive necrosis 
was observed (Fig. 2a, upper panel). The vascular architecture 
in the tumors was assessed by von Willebrand factor (vWF) 
antibody staining. In both tumors, a vascular normalization at 
the structural level was observed (Fig. 2a, lower panel). We 
have previously described the blood vessel architecture, fol-
lowing bevacizumab treatment for P3 tumors [27]. For the P13 
xenografts, also a strong reduction in areas of endothelial pro-
liferation was observed (Fig. 2b). As previously shown by us 
[27] and other groups [8, 47, 48], a significant increase in the 
number of tumor cells invading the normal brain was observed 
after bevacizumab treatment for both xenografts (Fig. 2a, 
lower panel and Fig. 2b). In summary, these results verify to a 
large extent results obtained from preclinical as well as clinical 
bevacizumab treatment studies.
Hypoxia is induced in the tumors after bevacizumab 
treatment
We have previously indicated that HIF1α is up-regulated in 
P3 tumors after bevacizumab treatment [27]. 18F-FMISO 
PET imaging on both xenograft models (n = 2 and n = 3 
per group for P3 and P13, respectively), at 1, 3 and 7 days, 
following treatment, revealed a strong signal increase in 
the treatment groups compared to controls during the 7 day 
treatment period, suggesting that bevacizumab causes a 
gradual increase of hypoxia in the tumors (Fig. 2c). Thus, 
it appears that bevacizumab leads to reduced oxygenation 
in the tumor at early (shown here) and late time points 
[27]. In this context, a vascular normalization window at a 
functional level, which implies improved oxygenation and 
reduced hypoxia, was not observed by 18F-FMISO PET 
during the first 7 days of treatment (Fig. 2c).
13C6-glucose metabolic flux analysis shows increased 
glycolysis after bevacizumab treatment
We have previously shown that bevacizumab induces 
higher levels of lactate in P3 tumors, suggesting an increase 
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Fig. 2  Bevacizumab induces reduction of contrast enhancement and 
normalization of vascular morphology. a Upper panels: T1 contrast-
enhanced MRI images of control and bevacizumab-treated P3 and 
P13 tumors at week 6 after implantation. A reduction in contrast 
enhancement is seen after bevacizumab treatment. Corresponding 
H&E-stained sections of P3 tumors showing a reduction in pseu-
dopalisading necrosis (insets), whereas this was not observed in the 
P13 tumors. (bars 100 µm). Lower panels: vWf factor staining of 
blood vessels in control P13 tumors showing a strong proliferation of 
endothelial cells at the tumor margin as indicated by numerous vascu-
lar nests. These nests were absent in the bevacizumab-treated tumors 
(bars 100 µm). P13 tumors stained with a nestin human monoclonal 
antibody show an increased invasion in bevacizumab-treated tumors 
compared to controls (bars 100 µm). b A significant reduction in 
blood vessels was observed for both P13 and P3 tumors following 
bevacizumab treatment, whereas in both tumors a significant increase 
in tumor cell invasion was seen. c 18F-FMISO PET images after the 
first week of bevacizumab treatment revealed a stronger hypoxia sig-
nal in both P3 and P13 tumors in the treatment groups (red arrows) 
compared to untreated control tumors (green arrows). For the P13 
tumors, the 18F-FMISO PET images were confirmed by immu-
nostaining for the hypoxyprobe pimonidazole (insets; bar 100 µm)
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in glycolytic activity [27]. We therefore performed a 
detailed metabolic flux analysis of the P3 xenografts. First, 
we infused 13C6-glucose i.v into normal rats and collected 
blood samples at 15, 20, 60 and 120 min after infusion. 
The blood samples were then subjected to LC–MS analysis 
where both 13C-labeled and unlabeled glucose were quan-
tified. These initial studies revealed a rather quick utiliza-
tion of glucose in the rats (Supplementary Fig. 2). Based on 
these results, we harvested the brain 15 and 120 min after 
13C6-glucose injection for metabolomic analysis. Tissues 
were collected from the main tumor mass as well as from 
the contralateral normal brain (Fig. 1). For metabolic anal-
ysis, metabolites were extracted from tumors and contralat-
eral brain samples and quantified by LC–MS ion counts. 
The data of the metabolite M + 0 mass isotopologue and of 
M + 6 glucose isotopologue were then normalized and ana-
lyzed by principal components analysis (PCA). Clustering 
of samples between brain and tumor, and between treated 
and control animals were evident 15 min after labeled glu-
cose injection (Fig. 3a, left panel). Distinctions between 
treated and control groups in brain or tumor samples were, 
however, less evident 120 min after injection (Fig. 3a, right 
panel).
A detailed analysis of metabolites 15 min after the 
injection of labeled 13C glucose revealed increased lev-
els of labeled glucose (m + 6) in the tumors of bevaci-
zumab-treated animals (Fig. 3b; left panel), suggesting 
an increased glucose flux after treatment. In agreement 
with this (increased glucose consumption), unlabeled 12C 
glucose and pyruvate were lower in the tumors of bevaci-
zumab-treated animals compared to control tumors. At the 
same time total lactate levels (both labeled and unlabeled) 
were significantly increased after treatment, indicating 
an uncoupling of glycolysis from oxidative phosphoryla-
tion in favor of lactate production (Fig. 3b; left panel). An 
increased production of labeled lactate was also observed 
in the healthy brain which may suggest an effect of bevaci-
zumab on normal brain cells or a contamination of the tis-
sue with infiltrating tumor cells.
The observations of increased glucose consumption 
were further substantiated by 18F-FDG micro-PET imag-
ing showing an increased uptake of this radioactive glu-
cose analog after treatment (Fig. 3b; right upper panel). 
As expected, concentrations of lactate measured in vivo by 
MRS showed a 17 % increase in the bevacizumab-treated 
animals (n = 15) compared to the control group (n = 17), 
confirming the results of the flux analysis (Fig. 3b; right 
lower panel).
We also assessed, after bevacizumab treatment, changes 
in expression of key enzymes associated with glycolysis 
and with the pentose phosphate pathway (PPP) in both the 
P3 and P13 xenografts. As shown in Fig. 3c, the glycolytic 
enzymes aldolase C (ALDOC), hexokinase 2 (HK2) and 
phosphofructokinase 1 (PFKP), as well as the PPP enzymes 
glucose-6-phosphate dehydrogenase (G6PD), phosphoglu-
conate dehydrogenase (PGD), transaldolase 1 (TALDO1) 
and transketolase (TKT) were significantly up-regulated 
at the transcriptome level, yet with a stronger trend in the 
P3 tumors compared to P13 (Fig. 3c, left panels). Of note, 
the enzymes G6PD and PGD are both NADPH-producing 
enzymes in the oxidative arm of the PPP which may con-
tribute to NADPH production in the tumors. Increased 
enzyme levels were further confirmed at the protein level 
for PDK1, PFKP, HK2 and TKT (Fig. 3c, middle and right 
panels).
In summary, the presented results provide definitive evi-
dence that bevacizumab treatment leads to an up-regulation 
of glycolysis, concomitantly with an activation of the PPP 
pathway which may represent a major carbon source for 
energy and biomass production in the treated tumors.
Bevacizumab treatment causes a reduction of metabolites 
associated with the tricarboxylic acid cycle (TCA cycle)
Based on the comprehensive datasets obtained by LC–MS 
analysis, we also determined the metabolite quantities asso-
ciated with the TCA cycle. Figure 4 shows the total level 
(12C unlabeled as well as 13C labeled) of key metabolites. 
In addition to a reduction in total glucose, glucose-6-phos-
phate (G6P) and pyruvate in the bevacizumab-treated 
tumors, we observed a significant reduction in cis-aconitate, 
Fig. 3  Increased glycolytic activity following bevacizumab treat-
ment. a Principal components analysis (PCA) revealed clustering of 
metabolites extracted at 15 min after 13C6-glucose injection in the 
different animal groups: control and bevacizumab-treated tumors 
and contralateral brain (left panel). Distinctions between treated and 
control groups were, however, not evident at 120 min after injection 
(right panel). b Left panel: metabolic 13C6 glucose carbon flux anal-
ysis of labeled (gray) and unlabeled (colored) metabolites. The 13C 
isotopologues reveal an increased influx of labeled glucose (m + 6) 
leading to an increase of labeled pyruvate (m + 3) and lactate 
(m + 3) in the bevacizumab treatment tumors compared to the con-
trols (dark gray bars: m + 3 isotopologues, light gray bars: m + 6 
isotopologs). Increased labeled lactate was also seen in the contralat-
eral brain upon treatment. Note that levels of unlabeled 12C glucose 
and pyruvate were reduced in treated tumors, while unlabeled lactate 
levels were increased, suggesting a depletion of the glucose pool in 
favor of lactate production (pink bars: untreated tumor, red bars: 
treated tumors). Right panel: 18F-FDG micro-PET imaging showing 
an increased uptake of this radioactive glucose analog after treat-
ment (arrowheads depict the 18F-FDG signal). In vivo MRS shows a 
17 % increase of lactate in the bevacizumab-treated animals confirm-
ing the results of the metabolic flux analysis. c Expression analysis 
of key metabolic enzymes. Left panel: RT-qPCR analysis shows an 
up-regulation of glycolytic enzymes (ALDOC, HK2 and PFKP) as 
well key enzymes of the pentose phosphate pathway (PPP) (G6PD, 
PGD, TALDO1 and TKT), in both P3 and P13 xenografts. Yet there is 
a stronger trend in P3 tumors compared to P13. Western blots (central 
panel) substantiated these observations indicating an up-regulation 
of PDK1, PFKP, HK2 and TKT protein after treatment. Right panel: 
quantification of the blots after normalization to β-actin
▶
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α-ketoglutarate, succinate, fumarate and malate (Fig. 4a). 
The results were similar for labeled and unlabeled metab-
olites indicating a strong correlation between these sub-
populations (Supplementary Fig. 3). Changes in these 
metabolites were also seen in the contralateral brain tissue, 
again suggesting that bevacizumab may also induce meta-
bolic changes in the normal brain, although this observa-
tion could also be explained by infiltrating tumor cells. In 
agreement with the flux analysis, these data indicate an 
uncoupling of glycolysis from the TCA cycle in favor of 
increased lactate production.
Interestingly, the data also revealed reduced levels of l-glu-
tamine upon treatment, suggesting that glutamine may be used 
to refuel the TCA cycle as a result of treatment (Fig. 4a).
Finally, the LC–MS analyses indicated that bevacizumab 
treatment led to a reduction in metabolites associated with 
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the γ-glutamyl cycle, such as cysteine, glutamate and gly-
cine, with a concomitant reduction in glutathione (Fig. 4b). 
Glutathione is known for its antioxidant properties by scav-
enging free radicals and reactive oxygen species; hence 
its depletion may be associated with increased oxidative 
stress. Since glutathione is recycled from oxidized glu-
tathione via NADPH consumption, we asked the question 
whether NADPH levels were affected by the treatment. 
Although we detected much higher levels of NADPH in 
tumors compared to normal brain, we did not see any dif-
ference in the NADP+/NADPH ratio between treated and 
untreated tumors (Supplementary Fig. 4).
In summary, the results from this in depth metabo-
lomic analysis strongly suggest that bevacizumab treat-
ment causes a shift from aerobic respiration to anaerobic 
metabolism. Moreover, reduced levels of glutathione indi-
cate that the treatment may induce oxidative stress in the 
tumors.
Lactate dehydrogenase (LDH) levels are increased 
in bevacizumab-treated tumors
Since an increased accumulation of lactate was observed 
in the metabolic flux study, we studied the expression of 
the enzyme lactate dehydrogenase (LDH) in the P3 and 
P13 xenografts by immunohistochemistry and by Western 
blots. LDH5 is the hypoxia-inducible isoform of the tetra-
meric enzyme LDH, composed of four identical subunits 
transcribed from the LDH-A gene [46]. For the P3 control 
tumors, LDHA was highly expressed toward the periphery 
(Fig. 5a, green arrows) as well as in hypoxic pseudopali-
sading necrotic areas in the tumor core (Fig. 5a, yellow 
arrows). The staining was increased and appeared more 
homogeneous after treatment as determined by intensity 
plots (Fig. 5a, right panels). Also in the P13 tumors, a 
strong up-regulation of LDHA was seen after bevaci-
zumab treatment. Western blots from both tumors con-
firmed the immunohistochemical observations (Fig. 5a, 
right panels).
To validate these observations in clinical specimens, we 
obtained tumor samples from eight GBM patients before 
and after bevacizumab treatment (see Supplementary 
Table 1 for patient characteristics).
Immunohistochemistry analysis of tumor tissue obtained 
before bevacizumab treatment showed LDHA to be mainly 
expressed by tumor cells located in perinecrotic areas 
(Fig. 5b) and to a lower extent in tumor cells outside these 
areas. In post-treatment samples, however, the LDHA 
expression changed into a patchy “leopard-skin”-like stain-
ing pattern displaying the highest frequency of LDHA-posi-
tive cells in the tumor center, but also a strong expression by 
diffusely infiltrating tumor cells (Fig. 5b). Matched-paired 
analyses of the patients revealed a significant increase of 
LDHA-positive cells in tumor centers as well as in infiltra-
tion zones after bevacizumab treatment (Fig. 5c). Since some 
tumors were taken from biopsies and others from autopsy 
material, we performed ANOVA analysis of LDHA expres-
sion after bevacizumab treatment with regard to biopsy vs. 
autopsy. This revealed no statistical difference between both 
conditions, in the infiltration zone (p = 0.9838) or in the 
tumor center (p = 0.5826) (Supplementary Fig. 5). In the 
infiltration zone, mean LDHA % in the biopsy group was 
29.53 (CI 10.617–48.45, median 35.2) and mean LDHA % 
in the autopsy group was 29.74 (CI 15.087–44.39, median 
27.2). In the tumor center, mean LDHA % in the biopsy 
group was 49.10 (CI 31.046–67.154, median 45.8) and mean 
LDHA % in the autopsy group was 29.74 (CI 15.087–44.39, 
median 27.2) (Supplementary Fig. 5a). No correlation was 
found between LDHA expression and last bevacizumab time 
to histology (r = 0.098; p = 0.8154), in the tumor center or 
in the infiltration zone (r = −0.179; p = 0.6708) (Supple-
mentary Fig. 5b). Immunofluorescence double staining with 
antibodies against CD68 ruled out that microglial cells were 
the source for LDH expression in the infiltration zone (Sup-
plementary Fig. 6).
In summary, the increased expression of LDH together 
with the increased levels of lactate suggests that bevaci-
zumab treatment leads to an acidification of the microen-
vironment caused by glycolysis. This acidification may 
not only occur in the tumor core, but also in the infiltrative 
compartment of GBMs.
Flow cytometric phenotyping indicates that the change 
in phenotype represents an adaptive response and is not 
caused by clonal evolution and cancer stem-like cell 
selection
An inevitable relapse of disease upon treatment may 
appear due to genetic or phenotypic cellular heterogeneity 
present within the tumor bulk [18, 41]. We have recently 
shown that GBMs display strong heterogeneity at the DNA 
ploidy level and at the level of stem cell marker expres-
sion [53]. We also found that aneuploidization is a late 
event in GBM development and that aneuploid cells show 
differential growth characteristics compared to pseudodip-
loid clones [53]. To assess whether bevacizumab treatment 
Fig. 4  Bevacizumab treatment causes a reduction of metabolites 
associated with the TCA cycle. a Total metabolite levels (unla-
beled and labeled) were quantified by LC–MS analysis. In addition 
to decreased glucose, glucose-6-phosphate and pryruvate levels, a 
reduction of metabolites associated with the TCA cycle was meas-
ured in the bevacizumab-treated tumors. These included pyruvate, 
cis-aconitate, α-ketoglutarate, succinate, fumarate and malate. More-
over, reduced levels of l-glutamine were observed following bevaci-
zumab treatment. b Bevacizumab treatment led to reduced levels of 
glutathione and metabolites associated with glutathione synthesis, 
including l-cysteine, l-glutamate and l-glycine
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leads to a selection of specific cell types within the tumors, 
we analyzed ploidy and copy number aberrations of tumor 
cells following treatment. To this aim, P3 spheroids were 
implanted intracranially in eGFP+ NOD/Scid mice [40], 
and tumor cells were recognized as GFP negative cells 
(Supplementary Fig. 7). Hoechst-based ploidy measure-
ments revealed that pseudodiploid tumor cells retained 
their initial ploidy upon bevacizumab treatment (Fig. 6a). 
Moreover, aCGH-based genomic analysis showed no new 
genetic aberrations appearing following treatment (data not 
shown).
Phenotypic heterogeneity has been associated with the 
presence of putative cancer stem-like cells that have been 
proposed to be responsible for drug resistance and tumor 
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relapse [55]. To assess whether anti-angiogenic treatment 
selects for a particular subpopulation of tumor cells, we 
analyzed expression profiles of cell membrane markers 
known to be expressed in GBM cell subpopulations. Flow 
cytometric analysis of the tumor cells revealed no change 
in expression of classical tumor membrane proteins such as 
EGFR and CD29 (Fig. 6b). Similarly, expression profiles of 
putative stem cell markers including CD133, CD15, CD44, 
A2B5 were unchanged upon treatment (Fig. 6c), suggest-
ing no selection for a particular tumor cell subtype and no 
adaptation toward a more stem-like phenotype.
In summary, we show that the genomic and stem cell-
associated profiles of the tumor cells remain stable after 
bevacizumab treatment, suggesting that the observed meta-
bolic changes occur as a result of an adaptive response of 
tumor cells, rather than from a selection of a particular sub-
population with increased resistance to treatment.
Discussion
Angiogenesis is a prominent feature in GBMs where an 
activation of the VEGF-A signal transduction pathway, 
mediated by autocrine and paracrine mechanisms, repre-
sents a prominent component of angiogenesis induction 
[45]. Based on promising phase II studies that suggested 
a reduction in tumor size and prolongation of progres-
sion-free survival with radiological response rates rang-
ing between 21 and 61 % for recurrent GBMs [28, 56], 
two large phase III clinical trials were initiated (AVAglio 
and RTOG 0825). Despite minor differences, the two trials 
showed that bevacizumab treatment had no effect on over-
all patient survival, but with a somewhat longer progres-
sion-free survival [6, 15]. Several mechanisms have been 
proposed on how tumors may resist anti-angiogenic therapy 
(reviewed in [32, 33, 51], yet the mechanisms behind this 
refractoriness are unclear. Preclinical models of other can-
cers suggest that antiangiogenic therapy may cause a tem-
porary vascular normalization leading to increased blood 
perfusion and improved oxygen delivery [25]. Initial stud-
ies on GBMs with cediranib, a pan-VEGF receptor tyrosine 
kinase inhibitor, showed structural normalization of blood 
vessels and reduced vessel leakage [2]. However, it was 
later found that only a small percentage of patients (7 out 
of 30) displayed a functional normalization of the vessels 
with increased blood perfusion [52]. We have previously 
shown in a preclinical model that characterizes human 
GBMs, that bevacizumab treatment causes an induction 
of hypoxia leading to reduced tumor perfusion [27]. The 
patient-derived xenograft models used in these studies have 
previously been shown to retain the histological features of 
human GBMs, including infiltrative growth, angiogenesis 
and necrosis, while maintaining the heterogeneity of tumor 
subpopulations and the genetic mutations of the primary 
tumor [16, 49, 58]. We therefore chose to use these models 
instead of syngeneic models or xenogeneic models estab-
lished from cell lines that frequently show genetic drift and 
clonal selection resulting in the loss of key histological 
and genomic features that characterize human GBMs [30]. 
In the present work, our previous observations on tumor 
hypoxia are further substantiated by in vivo 18F-FMISO 
PET imaging showing a gradual increase in hypoxia fol-
lowing treatment (Fig. 2c). This phenomenon has also been 
observed in the clinic [11, 20] where it has been shown to 
have a predictive value on patient survival after treatment 
onset [50]. Even though strong induction of hypoxia has 
been observed by us and other groups, it cannot be ruled 
out that an increased perfusion may occur locally or in a 
subset of patients following treatment. Although it is pres-
ently not clear if this phenomenon also occurs in bevaci-
zumab-treated patients, it will be interesting to determine 
the biomarker potential of oxygenation in GBM patients as 
has been suggested for cediranib [1].
To determine how GBMs adapt to bevacizumab treat-
ment, we performed a detailed 13C6-glucose metabolic flux 
analysis comparing untreated and treated tumors. Using 
glucose labeled with 13C on all the carbons it has been 
shown in glioma patients that glucose is cleaved glyco-
lytically for lactate production, but also that an important 
fraction of glucose carbons enter via pyruvate into the TCA 
cycle under physiological conditions [36]. Thus, the oxida-
tive mitochondrial metabolization of glucose is important 
in GBM for energy metabolism and to supply TCA-derived 
Fig. 5  Bevacizumab treatment leads to an increased lactate dehy-
drogenase (LDH) expression. a Immunohistochemical analysis of P3 
and P13 tumors show an increased expression of LDH in the bevaci-
zumab-treated tumors (bar 500 µm). For the P3 control tumors, LDH 
was highly expressed in the periphery (left panel; green arrows) as 
well as in hypoxic pseudopalisading necrotic areas (left panel; yel-
low arrows). Right panel, quantification of LDH expression in con-
trol and treated tumors (quantification was made over defined area 
of 3,122 µm, outlined in the immunostained sections). Western blots 
from both tumors confirmed the immunohistochemical observations 
(left panel). b Immunohistochemical analyses of human primary 
GBMs predominantly exhibit strong LDHA expression in tumor cells 
surrounding necroses (arrowheads upper middle, asterisks indicating 
necroses), while infiltration zones were virtually devoid of LDHA-
positive cells. After bevacizumab treatment the LDHA expression 
pattern changed from a virtually exclusive perinecrotic pattern to 
a patchy leopard-skin-like expression (arrowheads lower left) also 
in non-necrotic tumor centers (lower middle) as well as in infiltra-
tion zones (lower right). Infiltrating pleomorphic tumor cells (black 
arrowheads lower right) strongly express LDHA (white arrowhead 
blowup on lower right indicating mitotic figure). (t. center tumor 
center, inf. zone infiltration zone; scale bars: lower left 1 mm, lower 
middle and right 100 µm). c Quantification of matched-pairs analyses 
revealed higher frequencies of LDH-positive cells in tumor centers 
(p = 0.0137) as well as in infiltration zones (p = 0.0159) after beva-
cizumab treatment. The number of LDHA-positive cells where quan-
tified as fraction of the whole cell population
◀
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precursors for the synthesis of non-essential amino acids. 
We show that anti-angiogenic treatment leads to an 
increased influx of 13C6-glucose into the tumors with a 
subsequent increase in LDH and 13C-labeled lactate levels, 
while key metabolites associated with the TCA cycle are 
reduced following treatment. These data provide conclusive 
evidence that bevacizumab leads to hypoxic tumors with an 
increase in glycolytic activity and decreased oxidative res-
piration. The LC–MS analysis also revealed reduced levels 
of l-glutamine. These observations are in agreement with 
previous reports indicating that under hypoxia glutamine is 
used via reductive glutamine carboxylation to fuel macro-
molecule synthesis, in particular lipogenesis [38].
Interestingly, we also observed reduced levels of 
l-cysteine and l-cystathione as well as glutathione, sug-
gesting increased oxidative stress in the tumors following 
bevacizumab treatment. Since the NADP+/NADPH ratio in 
the tumor was unchanged following treatment, the reduc-
tion in glutathione may be related to reduced de novo syn-
thesis, as suggested by the changes in the carboxyl cycle 
metabolites. Maintenance of NADPH status is supported 
by our finding that key PPP enzymes are up-regulated fol-
lowing treatment, suggesting that this pathway is engaged 
to maintain NADPH and biomass production and ensure 
continued tumor growth even at low oxygen levels.
A previous study by Kathagen et al. [26] highlighted 
the metabolic flexibility of GBM cells, describing a 
switch between glycolysis and PPP activity following 
changes in environmental oxygen levels. In apparent con-
trast to our results, the group reported a down-regulation 
of PPP enzymes in response to severe hypoxia. However, 
it should be noted that the study investigated the response 
to acute changes of oxygenation, while our results are 
based on chronic hypoxic stress in vivo as also confirmed 
by 18F-FMISO imaging. Thus, it is plausible that an initial 
down-regulation of the PPP in response to acute or short-
term hypoxia is followed by increased PPP activity upon 
adaptation of the tumor cell to hypoxic conditions.
A key question is why the GBMs in our study turn to 
glycolysis following bevacizumab treatment that will give 
a growth advantage. In this context, a common property of 
many cancers is up-regulation of glycolysis, resulting in 
increased glucose consumption, frequently seen in clini-
cal tumor imaging. It has therefore been suggested that a 
persistent turnover of glucose to lactate even under aerobic 
conditions (Warburg effect) is an efficient means to increase 
Fig. 6  Flow cytometric analysis 
indicates that the change in phe-
notype represents an adaptive 
response and not clonal evolu-
tion and stem-like cell selec-
tion. a Hoechst-based ploidy 
measurements revealed that 
pseudodiploid P3 xenografts 
retained their initial ploidy 
after 3 weeks of bevacizumab 
treatment. b Flow cytometric 
phenotyping of tumor cells 
revealed no change in expres-
sion levels of classical glioma 
tumor cell membrane proteins 
such as EGFR, CD90, NG2 
and CD29. c Also expression 
of the putative glioma stem cell 
markers CD133, CD15, CD44, 
A2B5 remained the same after 
treatment
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biomass production and maintain high proliferation rates 
[14]. The up-regulation of glycolysis and the induction of 
microenvironmental acidosis after bevacizumab treatment 
may lead to a cellular adaptation, on the one hand main-
taining continued tumor growth and on the other hand pro-
mote invasion. Such adapted cells have a powerful growth 
advantage, which may promote unconstrained proliferation 
and invasion. Support for this view comes from intravital 
microscopy studies showing increased tumor cell invasion 
in areas with low pH levels in experimental models [10]. 
Also in our xenografts models, we observed an up-regu-
lation of LDH and increased lactate levels suggesting an 
acidification of the microenvironment. Interestingly, single 
invasive LDH-positive tumor cells were observed even in 
highly oxygenated normal brain areas following treatment, 
a phenomenon that was also observed in patient biopsies 
taken at various time points after treatment (Fig. 5). Thus, 
our findings were also validated in human biopsies. Simi-
lar results were recently reported in another study [19] in 
which lactate levels were assessed in vivo using multi-
voxel 1H MR spectroscopy. Elevated levels of lactate were 
reported in the tumor core. Yet, in the diffuse infiltrative 
areas, the levels of lactate were lower, possibly reflecting 
that the limited fraction of infiltrated cells in healthy tis-
sue is insufficient to significantly influence the lactate level 
measured at the scale of MRS voxels (mmol). It should, 
however, be emphasized that under normoxia, the LDH-
positive infiltrative cells, may convert lactate to pyruvate 
which may enter the TCA cycle. It is therefore still an open 
question if the infiltrative tumor cells are truly glycolytic.
To evaluate whether the changes observed after treat-
ment could be explained by a selection of a new genetic 
clone and/or putative stem cell-like populations with 
increased resistance to treatment, we performed flow cyto-
metric ploidy and multiparameter phenotypic marker stud-
ies on non-treated and treated tumors. We did not observe 
any changes in ploidy levels, genetic aberrations and stem-
like associated cell membrane marker profiles following 
bevacizumab therapy, suggesting that the change in cellu-
lar behavior after treatment represents an adaptive meta-
bolic response. Yet, further studies are warranted to delin-
eate in detail to what extent clonal subpopulations within 
GBMs contribute to the changes in metabolic phenotypes 
observed.
Our findings of increased intratumoral hypoxia and gly-
colytic activity, leading to increased acidification of the 
microenvironment and invasiveness, suggest that therapies 
that target the metabolic adaptation mechanisms may pro-
vide a synergistic effect on bevacizumab therapy. Indeed, a 
number of preclinical studies have started to show reduced 
tumor progression when bevacizumab is combined with 
inhibitors targeting evasion mechanisms related to invasion 
and metabolism [5, 7, 22, 24, 29, 34, 37, 39, 42].
In conclusion, we show that bevacizumab treatment 
causes a metabolic shift in the tumors toward glycolysis 
where the cells depend less on oxidative respiration to pro-
duce ATP. This makes the recurrent tumor cell populations 
less dependent on angiogenesis. Moreover, this shift sup-
ports the notion that H(+) diffuses from the proximal tumor 
microenvironment into adjacent normal tissues where it 
causes tissue remodeling that permits local invasion. In 
this context a future challenge will be to develop therapeu-
tic approaches that target adaptive metabolic responses in 
tumors as a result of therapy-induced perturbations.
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